Black Rock Inc. Oragenics Inc Transaction History

Black Rock Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.11 - $15.59 $142 - $20,189	-1,295 Reduced 0.1%	1,330,152 $146,000
Q3 2022 Nov 14, 2022	SELL	$0.23 - $14.18 $462 - $28,487	-2,009 Reduced 0.15%	1,331,447 $302,000
Q2 2022 Aug 12, 2022	BUY	$0.24 - $0.42 $4,334 - $7,585	18,060 Added 1.37%	1,333,456 $462,000
Q1 2022 May 12, 2022	BUY	$0.33 - $0.56 $222 - $378	675 Added 0.05%	1,315,396 $453,000
Q4 2021 Feb 10, 2022	BUY	$0.43 - $0.69 $3,078 - $4,939	7,159 Added 0.55%	1,314,721 $586,000
Q3 2021 Nov 09, 2021	BUY	$0.58 - $0.84 $925 - $1,339	1,595 Added 0.12%	1,307,562 $830,000
Q2 2021 Aug 11, 2021	BUY	$0.6 - $0.89 $783,580 - $1.16 Million	1,305,967 New	1,305,967 $921,000

Ticker OGEN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 116,395,000
Market Cap $36.1M
Description
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immuni...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.